Gillian McGovern

home / authors / gillian-mcgovern

Articles

Tezepelumab Shows Sustained Post-Treatment Benefit in Chronic Spontaneous Urticaria Despite Missed Primary Endpoint

Tezepelumab Shows Sustained Post-Treatment Benefit in Chronic Spontaneous Urticaria Despite Missed Primary Endpoint

Gillian McGovern
March 19th 2025

Tezepelumab reduced CSU activity post-treatment through week 32, suggesting a delayed, sustained TSLP blockade effect.

Differences in Anti-PD-1/CTLA-4 and Anti-PD-1/LAG-3 Reported in Recent Study

Differences in Anti-PD-1/CTLA-4 and Anti-PD-1/LAG-3 Reported in Recent Study

Gillian McGovern
December 22nd 2023

The study examined the mechanisms of action associated with immune checkpoint inhibitor combination therapies.

Lipid Imaging Mass Spectrometry Aids in Accurate Skin Cancer Diagnosis, Study Says

Lipid Imaging Mass Spectrometry Aids in Accurate Skin Cancer Diagnosis, Study Says

Gillian McGovern
December 5th 2023

Investigators used LIMS to classify melanoma samples as tumors and non-tumors.

Neuronal-Like Communication Between Non-Neuron Skin Cells May Initiate Melanoma

Neuronal-Like Communication Between Non-Neuron Skin Cells May Initiate Melanoma

Gillian McGovern
August 21st 2023

According to study authors, this electrical communication between skin cells may have the potential for therapeutic implications.

Latest Updated Articles

2 KOLs are featured in this series.
Published: September 19th 2024 | Updated: September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Published: March 11th 2025 | Updated: March 31st 2025
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Apoptosis-Based Skin Cancer Treatment Shows Promise
Published: March 15th 2025 | Updated: March 31st 2025
Apoptosis-Based Skin Cancer Treatment Shows Promise
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
Published: March 7th 2025 | Updated: March 31st 2025
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
Published: March 8th 2025 | Updated: March 31st 2025
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
Published: March 8th 2025 | Updated: March 31st 2025
Late-Breaking Data: Phase 3 Updates on Ruxolitinib Cream for Prurigo Nodularis
© 2025 MJH Life Sciences

All rights reserved.